A Study of PJ009 in Healthy Adult Volunteers

NCT ID: NCT06523101

Last Updated: 2024-07-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-28
• Study Completion Date: 2023-05-15

Brief Summary

The main aim of this clinical trial is to assess the safety of PJ009 in healthy adult volunteers aged 18-45. The main questions it aims to answer are:

• Is PJ009 safe in healthy adult? Participants will
• Receive single dose of PJ009 or placebo according to weight, and then multiple doses daily for 7 days,
• Stay in hospital for assessment.

Detailed Description

This is a single center, randomized, double-blind, placebo-controlled phase 1 clinical study, aiming to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PJ009 in healthy adult volunteers.

Conditions

Short Bowel Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

PJ009 group

Participants will receive a single dose of PJ009 on day1, and then multiple doses of PJ009 once daily for 7 days (day5-11). Three dose levels will be evaluated. subcutaneous injection

Group Type: EXPERIMENTAL

PJ009

Intervention Type: DRUG

Six participants in each dose level will be randomized to receive a single dose and/or multiple doses of PJ009 in a double-blind fashion.

PJ009 Placebo group

Participants will receive a single dose of PJ009 placebo on day1, and then once daily for 7 days (day5-11). subcutaneous injection

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Two participants in each dose level will be randomized to receive placebo in a double-blind fashion.

Interventions

PJ009

Six participants in each dose level will be randomized to receive a single dose and/or multiple doses of PJ009 in a double-blind fashion.

Intervention Type: DRUG

Placebo

Two participants in each dose level will be randomized to receive placebo in a double-blind fashion.

Intervention Type: DRUG

Other Intervention Names

Glucagon-like Peptide-2 (GLP-2) analogue

Eligibility Criteria

Inclusion Criteria

1. Voluntarily participate and sign the informed consent form;

2. Healthy male or female subjects;

3. Aged 18 to 45 years (inclusive), body weight ≥ 50kg; body mass index between 19.0 and 26.0 (inclusive), body mass index (BMI) = weight (kg)/height^2 (m^2);

4. Female subjects of childbearing age with negative serum pregnancy test results;

5. Eligible subjects of fertility must agree to use effective contraceptive measures or abstain from sex during the study and within 6 months after the study;

6. Be able to understand and comply with the requirements of the protocol and expected to complete the entire study process.

Exclusion Criteria

1. History of allergic diseases (including but not limited to asthma, urticaria, allergic rhinitis), drug allergy, or allergy to the ingredients of the investigational drug;

2. Used any drugs (including prescription drugs, over-the-counter drugs and Chinese herbal medicines) within 4 weeks before enrollment, except for external drugs that are not absorbed by the body; or used drugs known to cause significant damage to a certain organ within 12 weeks before enrollment;

3. History of any serious disease, including but not limited to digestive system, cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, neuropsychiatric system, blood system, immune system diseases and metabolic abnormalities, or neurological or mental disorders, such as epilepsy and dementia;

4. History of congenital hemolytic hyperbilirubinemia;

5. History of gallstones or gastrointestinal surgery;

6. History of colorectal cancer;

7. History of gastrointestinal diseases, such as malabsorption, Crohn's disease, etc;

8. History of rash or dermatitis;

9. The laboratory and auxiliary examination results meet any of the following conditions:

1. Abnormal electrocardiogram with clinical significance determined by the investigator;

2. Abnormal vital signs with clinical significance determined by the investigator;

3. Positive results of HIV-Ab, HCV-Ab, HBsAg or syphilis test;

4. Abnormal results of laboratory tests (blood routine, urine routine, blood biochemistry, coagulation function) with clinical significance;

5. Positive results of drug abuse or alcohol test;

6. Abnormal results of chest X-ray (anterior) with clinical significance determined by the investigator;

10. History of donating blood ≥ 200 mL within 12 weeks before enrollment, or plan to donate blood during the study;

11. History of major surgery within 12 weeks before enrollment;

12. History of alcohol abuse within 6 months before enrollment, that is, drinking more than 14 units of alcohol per week (1 unit = 12 ounces or 360 mL of beer, 1.5 ounces or 45 mL of liquor with an alcohol content of 40%, 5 ounces or 150 mL wine);

13. Smoke more than 5 cigarettes a day within 6 months before enrollment;

14. Participated in other clinical trials within 12 weeks before enrollment, or used similar drugs of the investigational drug;

15. Cannot tolerate venipuncture blood collection or have a history of needle or blood fainting;

16. Lactating, pregnant, or planning to become pregnant or conceive in the near future;

17. Poor compliance as assessed by the investigator;

18. The investigator believes the subject is unsuitable for participating in this clinical study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chongqing Peg-Bio Biopharm Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ruigang Hou

Role: PRINCIPAL_INVESTIGATOR

Second Hospital of Shanxi Medical University

Locations

The Second Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Countries

China

Other Identifiers

CQPJ-PJ009-001

Identifier Type: -

Identifier Source: org_study_id